Presentation TCT 2016 Debate: Is Left Atrial Appendage Closure Underutilized? Yes, It Should Be Offered to All Patients With Atrial Fibrillation (I Would Want It!) Presenter: Andreas Baumbach, David Hildick-Smith, Ted Feldman November 01, 2016
Presentation TCT 2016 TCT 25: Efficacy and Safety of Left Atrial Appendage Closure vs Medical Treatment in Atrial Fibrillation: A Network Meta-Analysis From Randomized Trials Presenter: Zahid Amin, Jacqueline Saw, Luis Nombela-Franco October 31, 2016
Presentation TCT 2016 Editorial perspective: Interventional Treatment of Atrial Fibrillation: Current Strategy and Unmet Needs Presenter: Vivek Y. Reddy October 31, 2016
Presentation TCT 2016 Implantable Thermo-reactive Pulmonary Venous Stent for Atrial Fibrillation (Fulgur) Presenter: Glenn Van Langenhove October 31, 2016
Presentation TCT 2016 Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure) Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia October 30, 2016
Presentation TCT 2016 Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide! Presenter: David R. Holmes Jr., Josep Rodés-Cabau, David Hildick-Smith October 30, 2016
Presentation TCT 2016 Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog October 30, 2016
Presentation TCT 2016 TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement Presenter: Jean-Claude Laborde, Azfar G. Zaman October 30, 2016
Presentation TCT 2016 Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger October 30, 2016
Presentation TCT 2016 Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy October 30, 2016
Presentation TCT 2016 What are Valid Absolute and Relative Contraindications to Warfarin and NOACs? Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt October 30, 2016
Presentation TCT 2016 Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue October 30, 2016
Presentation TCT 2016 Impact of LAA Exclusion on Neurohormonal Modulation Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt October 30, 2016
Presentation TCT 2016 Role of LAA in Atrial Arrhythmias: Origin and Maintenance Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt October 30, 2016
Presentation TCT 2016 Atrial Fibrillation: Scope of the Problem Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michael D. Ezekowitz October 30, 2016
Presentation TCT 2016 TAVR in Patients With Atrial Fibrillation Presenter: Neal S. Kleiman, Patrick T. O'Gara, Fabian Nietlispach October 30, 2016
Presentation TCT 2016 Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx October 30, 2016
Presentation ESC 2016 Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation Presenter: Andreas Goette August 30, 2016
Presentation Outcomes of Patients With Atrial Fibrillation Undergoing PCI Presenter: NR. Sutton August 24, 2016
Presentation TVT 2016 Combined TAVR and Left Atrial Appendage Closure in AS Patients With Atrial Fibrillation: Case Selection, Procedural Consideration, and Clinical Outcomes Presenter: Fabian Nietlispach June 17, 2016